GENEVA — Factors such as age and comorbidities appeared associated with longer time to melanoma diagnosis, according to study results presented at World Cancer Congress.
2022
Tebentafusp-tebn Use in HLA-A*02:01–Positive Unresectable or Metastatic Uveal Melanoma
The agent is representative of a new class of drug, ImmTAC.
Research Spotlight: Comparing Proton Beam Therapy and Plaque Brachytherapy in Ocular Melanoma
What was the question you set out to answer with this study?
Bexmarilimab Derives Overall Survival Benefit in PD-1 Blockade Refractory Melanoma
Results from the melanoma cohort of the phase 1/2 MATINS show the potential of bexmarilimab monotherapy and combined with other immunotherapies across solid tumors and hematologic malignancies.